This role of inflammation in atherosclerosis is further supported by evidence that targeting the proinflammatory cytokine interleukin-1β (IL-1β) with canakinumab reduced recurrent cardiovascular events by 15% in patients with established atherosclerosis, irrespective of lipid levels7. The gene discussed is IL1B; the disease is atherosclerosis.